Analyzing the Future of Imfinzi (durvalumab) Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Future CAGR of the Imfinzi (durvalumab) Market, and How Will It Impact Industry Expansion?
The market for imfinzi (durvalumab) has seen a quick expansion in the last few years. It is projected to increase from $2,701.22 million in 2024 to $3,013.33 million in 2025, with a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historic period include broadened indications and licenses, a surge in demand for targeted treatments, an increased interest in personalized therapies among patients, developments in immunotherapy, and a growing preference for immunotherapies among patients.
In the coming years, the market size of imfinzi (durvalumab) is projected to expand significantly, reaching $4,143.36 million in 2029 with a compound annual growth rate (CAGR) of 11.3%. The projected surge during this period can be attributed to factors such as the escalating use of combination therapies, an increase in pharmaceutical Research and Development activities, a rising incidence rate of cancer, greater acceptance of immunotherapy, a growing regulatory environment, and increased investment in healthcare facilities. Key trends expected during this forecast period include, embracing personalized medicine techniques, a shift towards personalized medicine, adoption of biosimilars, incorporating artificial intelligence and machine learning, and partnerships among pharmaceutical companies.
What Are the Primary Drivers Supporting the Growth of the Imfinzi (durvalumab) Market?
The accelerating occurrence of cancer is projected to contribute to the expansion of the Imfinzi (durvalumab) market’s future. A set of conditions characterized by the unregulated proliferation and dispersion of irregular cells in the body that can infiltrate and annihilate normal tissue is what encompasses cancer. The growing cancer rate is fueled primarily by an ageing populace, as the cancer risk amplifies with age, and lifestyle aspects such as smoking, poor nutrition, and obesity, contributing to an increase in cancer incidences. Imfinzi (durvalumab) is utilized to fight cancer by impeding the PD-L1 protein, which stops cancer cells from avoiding recognition by the immune system. The National Cancer Institute (NIH), a governing agency in the U.S, stated in May 2024 that in 2022 there were 18.1 million cancer survivors, predicted to magnify to 22.5 million by 2032 in the US. Consequently, the accelerating occurrence of cancer is a major factor driving the expansion of the Imfinzi (durvalumab) market.
Explore Comprehensive Insights Into The Global Imfinzi (durvalumab) Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp
What Are the Top Market Players Propelling the Growth of the Imfinzi (durvalumab) Industry?
Major companies operating in the imfinzi (durvalumab) market include AstraZeneca PLC.
What Are the Key Trends to Watch in the Imfinzi (durvalumab) Market Over the Coming Years?
One primary trend in the imfinzi (durvalumab) market involves targeting regulatory approval to augment its usage for diverse cancer types, bolster its clinical indications, and enhance its market presence. Regulatory permissions constitute formal permission extended by health regulators like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for a drug, medical tool, or treatment to be promoted and administered within specific regions. For example, in September 2022, UK pharmaceutical firm AstraZeneca was granted FDA authorization for durvalumab (Imfinzi) to treat locally advanced or metastatic biliary tract cancer (BTC) in adults. This was based on results from the pivotal TOPAZ-1 trial, which evidenced significant improvements in overall survival (12.8 months vs. 11.5 months with placebo) and progression-free survival (7.2 months vs. 5.7 months) when durvalumab was mixed with gemcitabine and cisplatin. The trial enlisted 685 patients with various BTC forms, reporting common side-effects like fatigue, nausea, and abdominal pain. The suggested dose is 1,500 mg every three weeks during combination therapy, followed by monotherapy every four weeks.
Secure Your Global Imfinzi (durvalumab) Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report
Which Key Market Segments Comprise the Imfinzi (durvalumab) Market and Drive Its Revenue Growth?
The imfinzi (durvalumab)market covered in this report is segmented –
1) By Type: 2.4mL Injection; 10mL Injection
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
What Regions Are Dominating the Imfinzi (durvalumab) Market Growth?
North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Characteristics That Define the Imfinzi (durvalumab) Market?
Imfinzi (durvalumab) is a human monoclonal antibody and an immunotherapy drug specifically designed to block programmed death-ligand 1 (PD-L1), a protein that tumors use to evade detection by the immune system. It is used to treat various cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.
Browse Through More Similar Reports By The Business Research Company:
Autoimmune Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025
mRNA Cancer Vaccines And Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
